Sessions included:
- BD01 – DMTs prevent-slow down cognitive impairment in MS
- BD02 – DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity
- BD03 – Microglia are protective in MS
- CS01 – European Charcot Foundation Symposium; How to enhance remyelination in MS
- FC01 – Free Communication 1
- FC02 – Free Communication 2
- FC03 – Free Communication 3
- FC04 – Free Communication 4
- HT01 – Hot Topic 1- Strategies to promote remyelination
- HT02 – Hot Topic 2- Aging and MS
- HT03 – Hot Topic 3- Developments in pediatric MS
- HT04 – Hot Topic 4- Grey matter pathology
- HT05 – Hot Topic 5- Lymphoid follicles and meningeal involvement in MS
- HT06 – Hot Topic 6- Global perspectives on NMOSD
- HT07 – Hot Topic 7- MOG mediated disease
- LB01 – Late Breaking News
- MTE01 – CNS in disorders in children
- MTE02 – Neuro-ophthalmology of MS
- MTE03 – B-cell-directed therapy in MS
- MTE04 – Choosing the right MS disease therapy for individual patients
- MTE05 – Immune disorders of the CNS other than MS
- NS01 – Nurses’ Session 1- Advanced nursing activities
- NS02 – Nurses’ Session 2- Unique contributions of MS nursing
- PL01 – Plenary Session 1- Welcome and Paty Lecture
- PL02 – Plenary Session 2- ACTRIMS-ECTRIMS Lecture and Closing
- PS01 – Strategies for disease modification
- PS02 – Innate immunity in MS pathology and repair
- PS03 – Biomarkers
- PS04 – Impact of the environment and lifestyle and MS risk and clinical course
- PS05 – Pharmacological management of progressive MS
- PS06 – Lymphocyte subsets in MS
- PS07 – Radiological advances I (NAIMS-MAGNIMS)
- PS08 – Epigenetics and genetic factors
- PS09 – Personalized approaches to MS
- PS10 – Gut-CNS axis and the microbiome in MS
- PS11 – Radiological advances II
- PS12 – Sex-related factors in pathogenesis and management
- PS13 – Innovations in symptomatic and rehabilitative therapy
- PS14 – The impact of MS on neurons and glia
- PS15 – Visual outcome measures in MS (IMSVISUAL)
- PS16 – Machine learning approaches
- SS02 – Special Session- COVID-19
- YI01 – Young Investigators 1
- YI02 – Young Investigators 2
